Combalia Andrea, Carrera Cristina
Dermatology Department, University of Barcelona, Hospital Clínic de Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto Carlos III, Barcelona, Spain.
Dermatol Pract Concept. 2020 Jun 29;10(3):e2020066. doi: 10.5826/dpc.1003a66. eCollection 2020 Jul.
Squamous cell carcinoma (SCC) accounts for most nonmelanoma skin cancer-related metastatic disease and deaths. Histopathology and correct surgical excision remain the gold standard for the diagnosis and treatment of SCC; however, new diagnostic imaging techniques such as dermoscopy and reflectance confocal microscopy have increased the diagnostic accuracy in terms of early recognition, better differential diagnosis, more precise selection of areas to biopsy, and noninvasive monitoring of treatments. The therapeutic intervention in patients with severe actinic damage and multiple in situ/low-risk SCC, and the development of innovative treatments such as epidermal growth factor receptor inhibitors and immune checkpoint inhibitors for locally advanced and metastatic SCC, are improving considerably the approach to the disease. This review summarizes the up-to-date knowledge in the field of detection, treatment, and monitoring of cutaneous SCC.
鳞状细胞癌(SCC)是大多数与非黑色素瘤皮肤癌相关的转移性疾病和死亡的原因。组织病理学和正确的手术切除仍然是SCC诊断和治疗的金标准;然而,新的诊断成像技术,如皮肤镜检查和反射式共聚焦显微镜检查,在早期识别、更好的鉴别诊断、更精确地选择活检部位以及对治疗进行无创监测方面提高了诊断准确性。对于患有严重光化性损伤和多发原位/低风险SCC的患者的治疗干预,以及针对局部晚期和转移性SCC的表皮生长因子受体抑制剂和免疫检查点抑制剂等创新治疗方法的开发,正在显著改善对该疾病的治疗方法。本综述总结了皮肤SCC检测、治疗和监测领域的最新知识。